Literature DB >> 27799408

Congenital valvular defects associated with deleterious mutations in the PLD1 gene.

Asaf Ta-Shma1,2, Kai Zhang3, Ekaterina Salimova4, Alma Zernecke5, Daniel Sieiro-Mosti4, David Stegner5, Milena Furtado4, Avraham Shaag2, Zeev Perles1, Bernhard Nieswandt5, Azaria J J T Rein1, Nadia Rosenthal4, Aaron M Neiman3, Orly Elpeleg2.   

Abstract

BACKGROUND: The underlying molecular aetiology of congenital heart defects is largely unknown. The aim of this study was to explore the genetic basis of non-syndromic severe congenital valve malformations in two unrelated families.
METHODS: Whole-exome analysis was used to identify the mutations in five patients who suffered from severe valvular malformations involving the pulmonic, tricuspid and mitral valves. The significance of the findings was assessed by studying sporulation of yeast carrying a homologous Phospholipase D (PLD1) mutation, in situ hybridisation in chick embryo and echocardiography and histological examination of hearts of PLD1 knockout mice.
RESULTS: Three mutations, p.His442Pro, p.Thr495fs32* and c.2882+2T>C, were identified in the PLD1 gene. The mutations affected highly conserved sites in the PLD1 protein and the p.His442Pro mutation produced a strong loss of function phenotype in yeast homologous mutant strain. Here we show that in chick embryos PLD1 expression is confined to the forming heart (E2-E8) and homogeneously expressed all over the heart during days E2-E3. Thereafter its expression decreases, remaining only adjacent to the atrioventricular valves and the right ventricular outflow tract. This pattern of expression follows the known dynamic patterning of apoptosis in the developing heart, consistent with the known role of PLD1 in the promotion of apoptosis. In hearts of PLD1 knockout mice, we detected marked tricuspid regurgitation, right atrial enlargement, and increased flow velocity, narrowing and thickened leaflets of the pulmonic valve.
CONCLUSIONS: The findings support a role for PLD1 in normal heart valvulogenesis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Congenital heart defects

Mesh:

Substances:

Year:  2016        PMID: 27799408     DOI: 10.1136/jmedgenet-2016-104259

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  15 in total

1.  Heterozygous De Novo UBTF Gain-of-Function Variant Is Associated with Neurodegeneration in Childhood.

Authors:  Simon Edvardson; Claudia M Nicolae; Pankaj B Agrawal; Cyril Mignot; Katelyn Payne; Asuri Narayan Prasad; Chitra Prasad; Laurie Sadler; Caroline Nava; Thomas E Mullen; Amber Begtrup; Berivan Baskin; Zöe Powis; Avraham Shaag; Boris Keren; George-Lucian Moldovan; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2017-08-03       Impact factor: 11.025

2.  Biallelic variants in AGTPBP1, involved in tubulin deglutamylation, are associated with cerebellar degeneration and motor neuropathy.

Authors:  Ruth Sheffer; Michal Gur; Rebecca Brooks; Somaya Salah; Muhannad Daana; Nitay Fraenkel; Eli Eisenstein; Malcolm Rabie; Yoram Nevo; Chaim Jalas; Orly Elpeleg; Shimon Edvardson; Tamar Harel
Journal:  Eur J Hum Genet       Date:  2019-04-11       Impact factor: 4.246

3.  Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathy.

Authors:  Najim Lahrouchi; Alex V Postma; Christian M Salazar; Daniel M De Laughter; Fleur Tjong; Lenka Piherová; Forrest Z Bowling; Dominic Zimmerman; Elisabeth M Lodder; Asaf Ta-Shma; Zeev Perles; Leander Beekman; Aho Ilgun; Quinn Gunst; Mariam Hababa; Doris Škorić-Milosavljević; Viktor Stránecký; Viktor Tomek; Peter de Knijff; Rick de Leeuw; Jamille Y Robinson; Sabrina C Burn; Hiba Mustafa; Matthew Ambrose; Timothy Moss; Jennifer Jacober; Dmitriy M Niyazov; Barry Wolf; Katherine H Kim; Sara Cherny; Andreas Rousounides; Aphrodite Aristidou-Kallika; George Tanteles; Bruel Ange-Line; Anne-Sophie Denommé-Pichon; Christine Francannet; Damara Ortiz; Monique C Haak; Arend D.J. Ten Harkel; Gwendolyn Tr Manten; Annemiek C Dutman; Katelijne Bouman; Monia Magliozzi; Francesca Clementina Radio; Gijs We Santen; Johanna C Herkert; H Alex Brown; Orly Elpeleg; Maurice Jb van den Hoff; Barbara Mulder; Michael V Airola; Stanislav Kmoch; Joey V Barnett; Sally-Ann Clur; Michael A Frohman; Connie R Bezzina
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

4.  EPT1 (selenoprotein I) is critical for the neural development and maintenance of plasmalogen in humans.

Authors:  Yasuhiro Horibata; Orly Elpeleg; Ayelet Eran; Yoshio Hirabayashi; David Savitzki; Galit Tal; Hanna Mandel; Hiroyuki Sugimoto
Journal:  J Lipid Res       Date:  2018-03-02       Impact factor: 5.922

5.  Unique Ataxia-Oculomotor Apraxia 2 (AOA2) in Israel with Novel Variants, Atypical Late Presentation, and Possible Identification of a Poison Exon.

Authors:  Vardiella Meiner; Alexander Lossos; Hagit Baris Feldman; Penina Ponger; Alina Kurolap; Israela Lerer; Judith Dagan; Chofit Chai Gadot; Adi Mory; Yael Wilnai; Nino Oniashvili; Nir Giladi; Tanya Gurevich
Journal:  J Mol Neurosci       Date:  2022-06-08       Impact factor: 2.866

6.  Loss of function mutations in CCDC32 cause a congenital syndrome characterized by craniofacial, cardiac and neurodevelopmental anomalies.

Authors:  Tamar Harel; John N Griffin; Thomas Arbogast; Tanner O Monroe; Flavia Palombo; Marcella Martinelli; Marco Seri; Tommaso Pippucci; Orly Elpeleg; Nicholas Katsanis
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

7.  De Novo Missense Mutations in DHX30 Impair Global Translation and Cause a Neurodevelopmental Disorder.

Authors:  Davor Lessel; Claudia Schob; Sébastien Küry; Margot R F Reijnders; Tamar Harel; Mohammad K Eldomery; Zeynep Coban-Akdemir; Jonas Denecke; Shimon Edvardson; Estelle Colin; Alexander P A Stegmann; Erica H Gerkes; Marine Tessarech; Dominique Bonneau; Magalie Barth; Thomas Besnard; Benjamin Cogné; Anya Revah-Politi; Tim M Strom; Jill A Rosenfeld; Yaping Yang; Jennifer E Posey; LaDonna Immken; Nelly Oundjian; Katherine L Helbig; Naomi Meeks; Kelsey Zegar; Jenny Morton; Jolanda H Schieving; Ana Claasen; Matthew Huentelman; Vinodh Narayanan; Keri Ramsey; Han G Brunner; Orly Elpeleg; Sandra Mercier; Stéphane Bézieau; Christian Kubisch; Tjitske Kleefstra; Stefan Kindler; James R Lupski; Hans-Jürgen Kreienkamp
Journal:  Am J Hum Genet       Date:  2017-11-02       Impact factor: 11.025

8.  Heterozygous RNF13 Gain-of-Function Variants Are Associated with Congenital Microcephaly, Epileptic Encephalopathy, Blindness, and Failure to Thrive.

Authors:  Simon Edvardson; Claudia M Nicolae; Grace J Noh; Jennifer E Burton; Giuseppe Punzi; Avraham Shaag; Jessica Bischetsrieder; Anna De Grassi; Ciro Leonardo Pierri; Orly Elpeleg; George-Lucian Moldovan
Journal:  Am J Hum Genet       Date:  2018-12-27       Impact factor: 11.025

9.  A mutation in POLR3E impairs antiviral immune response and RNA polymerase III.

Authors:  Aravind Ramanathan; Michael Weintraub; Natalie Orlovetskie; Raphael Serruya; Dhivakar Mani; Orly Marcu; Polina Stepensky; Yiska Weisblum; Esther Djian; Avraham Shaag; Shoshana Revel-Vilk; Iris Fried; Moshe Kotler; Alex Rouvinski; Dana Wolf; Orly Elpeleg; Nayef Jarrous
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-25       Impact factor: 11.205

10.  Loss of ADAMTS19 causes progressive non-syndromic heart valve disease.

Authors:  Florian Wünnemann; Asaf Ta-Shma; Gregor Andelfinger; Christoph Preuss; Severine Leclerc; Patrick Piet van Vliet; Andrea Oneglia; Maryse Thibeault; Emily Nordquist; Joy Lincoln; Franka Scharfenberg; Christoph Becker-Pauly; Philipp Hofmann; Kirstin Hoff; Enrique Audain; Hans-Heiner Kramer; Wojciech Makalowski; Amiram Nir; Sebastian S Gerety; Matthew Hurles; Johanna Comes; Anne Fournier; Hanna Osinska; Jeffrey Robins; Michel Pucéat; Orly Elpeleg; Marc-Phillip Hitz
Journal:  Nat Genet       Date:  2019-12-16       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.